Introduction: Adenoid cystic carcinoma (ACC) is a rare tumor of the salivary glands, with slow growth but high potential for perineural invasion and metastasis. Genetic alterations, such as MYB gene rearrangements and DNA copy number variations (CNAs), are common in these tumors. Although surgery is the standard treatment, its efficacy is limited in metastatic cases, and the scarcity of in vitro models hinders progress in translational research. Objectives: To characterize morphologically and genetically a cell line derived from ACC. Methods: The study was approved by the Research Ethics Committee of the Federal University of Pará (CAAE: 09239518.9.0000.0018). A tumor fragment located in the trigone of the salivary gland was obtained from a 59-year-old female patient treated at Hospital Ophir Loyola. After washing and mechanical dissociation, a portion of the sample was used for DNA extraction and the other was cultured in D-MEM medium, incubated at 37°C with 5% CO?. Cell proliferation kinetics were analyzed at passage 45, and the growth curve was generated using GraphPad Prism. A total of 3.17×10³ cells/well were seeded and counted at 24, 48, 72, and 96 hours. DNA was extracted from tumor tissue and the 59th cell passage using the QiAmp DNA Isolation Kit, followed by quantification with Nanodrop and validation via agarose gel electrophoresis. Morphological analysis was performed by histopathology. Immunophenotyping was conducted by immunofluorescence using antibodies against vimentin, cytokeratin AE1/AE3, cytokeratin 19 (CK19), and alpha-smooth muscle actin (?-SMA). Cytogenetic analysis was performed using array comparative genomic hybridization (aCGH) with the SurePrint G3 CGH+SNP platform (Agilent), considering significant alterations those with logRatio > 0.25 or < -0.25. Results: Histopathological analysis of the tumor revealed basaloid myoepithelial cells, tubular growth pattern, perineural invasion, and muscle infiltration. The derived NAT cell line exhibited an adherent phenotype and reached stable growth after the 30th passage, without the need for genetic manipulation for immortalization. The growth curve showed exponential proliferation over the 96-h observation period, with no stationary phase and a doubling time of approximately 29.4 h. Immunofluorescence revealed high expression of vimentin, low expression of AE1/AE3, and moderate expression of CK19 and ?-SMA, suggesting a predominantly mesenchymal and myoepithelial phenotype. aCGH analysis showed shared alterations between the tumor and the cell line, including amplifications at 8p11.22 (ADAM9) and 22q11.22 (MAPK1), and a deletion at 19p13.2 affecting the CDKN2D, KEAP1 and SMARCA1 genes. Conclusion: According to the proposal of this work, it was possible to characterize morphologically and genetically the cell line originating from ACC. The genomic alterations identified highlight its value as a representative model for the investigation of molecular mechanisms, for the development of biomarkers and targeted therapies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/